• Neurogenic bladder (SCI) patients

• OAB patients

• IC/BPS patients

• Male lower urinary tract dysfunction

• Female urinary incontinence and pelvic dysfunction•

Buddhist Tzu Chi Medical Foundation, Hualien Tzu Chi Hospital Department of Urology, led by Director Hann-Chorng Kuo, has built "Spin Dry, Happy Voiding" services—world-leading clinical treatment and research on botulinum toxin in lower urinary tract dysfunction. Expertscape global ranking: Tzu Chi University Kuo, H.-C. (54 publications) is global #1, surpassing UBC, U Penn, Auckland, Alabama, Rostock, UC Irvine, Philadelphia, Vanderbilt, etc. Eight botulinum toxin injection sites: muscle for incontinence, urothelium for IC, male/female urethra for voiding difficulty, detrusor for neurogenic bladder, trigone for bladder sensitivity/overactivity, transurethral prostate for BPH obstruction. Cumulative treatment exceeds 1,500 cases; multiple publications in SCI journals (Eur Urol IF 17.298, J Urol IF 5.647). Videourodynamic study (VUDS) center is internationally renowned training hub: 2015-2019 trained 18 domestic (NTU, NCKU, Chi Mei, MMH, Changhua Christian, etc.) and 12 international (Singapore, Malaysia, Philippines, Fujian, Shanghai) trainees. 2016-2019 cross-border patients 65 (Malaysia, China, Indonesia, Spain, Singapore, UK, Canada, Germany, Philippines). Top-cited Urology 2014 paper cited 219 times. Prof. Kuo's 54 publications rank #1 globally on Expertscape.

• #1 globally on Expertscape (urology botulinum toxin)

• 8 injection sites covering full LUT disorder spectrum

• Internationally renowned VUDS training center

• Cross-border patients from 9 countries

• Multiple world-first treatments of botulinum toxin in urology

• Liposome-encapsulated botulinum toxin bladder instillation

• 1,500+ cumulative treatments

• 65 cross-border patients (4 years)

• 18 domestic trainees (5 years)

• 12 international trainees

• Cumulative SCI publications

• High IF: Eur Urol, J Urol, BJU Int, etc.

• Neurogenic bladder satisfaction 60-90%

• OAB satisfaction 66.3-72%

• Male LUTS satisfaction 50-61.1%

• IC/BPS satisfaction 57.6-71%

• PRP for IC satisfaction 87%

• Urology 2014 cited 219 times

• Well-controlled adverse reactions (3-30% UTI)

• Acute urinary retention 5-8.3%

• Standardized injection dose and site

• International patient telemedicine consultation

• Multiple evidence-based clinical publications

• Large-sample long-term follow-up

• Patient testimonials (Xing-Yi mother case)

• Multiple northern hospitals refer to Hualien

• Patients travel far to seek treatment

• Taoyuan N+ family appreciation

• Resolves long-term voiding difficulty

• Improves patient quality of life

• Expertscape #1 globally (54 publications)

• Eur Urol IF 17.298, J Urol IF 5.647, BJU Int IF 4.524 (multiple)

• Urology 2014 cited 219 times

• Trainees from multiple countries

• Cross-border patients from 9 countries

• Surpasses UBC, U Penn, Auckland

• International leader in urology botulinum toxin application

• Drives standardized LUT dysfunction treatment

• Trained 30 domestic/intl staff in 5 years

• Establishes guidelines for domestic/intl medical centers

• Resolves voiding difficulty for patients from multiple countries

• Innovation in liposome-encapsulated botulinum toxin